Who
Patrick Burnett
Officer
Company insider
Files Form 4 as: Officer, Arcutis Biotherapeutics; Chief Medical Officer, Verrica Pharmaceuticals.
In numbers
- Trades disclosed
- 125
- Buys
- 0
- Sells
- 46
- Bought
- $0
- Sold
- $7.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 28 Feb 2019
- Last trade
- 19 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 21 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $46K1,697 at $27.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $46K1,697 at $27.00 | filing |
| 12 Aug 2026filed 13 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $24K6,700 at $3.64 | filing |
| 12 Aug 2026filed 13 Aug 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,700 at $0.00 | filing |
| 12 Aug 2026filed 13 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $175K6,700 at $26.08 | filing |
| 12 Aug 2026filed 13 Aug 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,700 at $0.00 | filing |
| 12 Aug 2026filed 13 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $24K6,700 at $3.64 | filing |
| 12 Aug 2026filed 13 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $175K6,700 at $26.08 | filing |
| 11 Aug 2026filed 13 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $30K8,300 at $3.64 | filing |
| 11 Aug 2026filed 13 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $220K8,300 at $26.52 | filing |
| 11 Aug 2026filed 13 Aug 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,300 at $0.00 | filing |
| 11 Aug 2026filed 13 Aug 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,300 at $0.00 | filing |
| 11 Aug 2026filed 13 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $30K8,300 at $3.64 | filing |
| 11 Aug 2026filed 13 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $220K8,300 at $26.52 | filing |
| 3 Aug 2026filed 5 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $25K955 at $26.12 | filing |
| 3 Aug 2026filed 5 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $25K955 at $26.12 | filing |
| 11 May 2026filed 13 May 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $4,673222 at $21.05 | filing |
| 11 May 2026filed 13 May 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $4,673222 at $21.05 | filing |
| 4 May 2026filed 6 May 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $16K684 at $23.61 | filing |
| 4 May 2026filed 6 May 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $16K684 at $23.61 | filing |
News
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbARQT · insidermonkey.com · 20 Oct 2026
0 headlines in the last 90 days name Patrick Burnett; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.